Department of Physiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia, EU.
Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia, EU.
Pediatr Pulmonol. 2018 Sep;53(9):1318-1325. doi: 10.1002/ppul.24082. Epub 2018 Jun 15.
Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the hydrolysis of phosphodiester bonds of 3',5' cyclic adenosine and guanosine monophosphate (cAMP and cGMP). PDEs control hydrolysis of cyclic nucleotides in many cells and tissues. Inhibition of PDEs by selective or nonselective PDE inhibitors represents an effective targeted strategy for the treatment of various diseases including respiratory disorders. Recent data have demonstrated that PDE inhibitors can also be of benefit in respiratory distress in neonates. This article outlines the pharmacological properties of nonselective and selective PDE inhibitors and provides up-to-date information regarding their use in experimental models of neonatal respiratory distress as well as in clinical studies.
磷酸二酯酶（PDEs）是一个超家族的酶，可催化 3'，5'环腺苷酸和鸟苷单磷酸（cAMP 和 cGMP）的磷酸二酯键的水解。PDEs 控制许多细胞和组织中环核苷酸的水解。通过选择性或非选择性 PDE 抑制剂抑制 PDE 代表了治疗各种疾病（包括呼吸障碍）的有效靶向策略。最近的数据表明，PDE 抑制剂也可能对新生儿呼吸窘迫有益。本文概述了非选择性和选择性 PDE 抑制剂的药理学特性，并提供了有关其在新生儿呼吸窘迫实验模型以及临床研究中的应用的最新信息。
